SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-101406
Filing Date
2021-03-31
Accepted
2021-03-31 07:53:02
Documents
14
Period of Report
2021-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d125044d8k.htm   iXBRL 8-K 25387
2 EX-99.1 d125044dex991.htm EX-99.1 49641
6 GRAPHIC g125044g0330075716681.jpg GRAPHIC 4594
  Complete submission text file 0001193125-21-101406.txt   215467

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20210331.xsd EX-101.SCH 3093
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20210331_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20210331_pre.xml EX-101.PRE 11423
7 EXTRACTED XBRL INSTANCE DOCUMENT d125044d8k_htm.xml XML 3421
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 21789859
SIC: 2834 Pharmaceutical Preparations